Learning from the trials of the immune checkpoint inhibitor therapies, it is possible to design novel approaches targeting the IGM-type of cancer plasticity: early clinical examples are CD20 [93], CD27/CD70 [109], CD166 [110], and IDO [111]. This evidence concerns the gene CD27 and cancer.